Found: 1108
Select item for more details and to access through your institution.
Role of Metformin Monotherapy Vs Metformin Plus Dapagliflozin in New Onset T2DM Among 40 Plus Obese Women in Glycaemic Control.
- Published in:
- JK Science, 2024, v. 26, n. 4, p. 209
- By:
- Publication type:
- Article
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand: SGLT2i for Thai Diabetes with HF Patients: T. Kongmalai et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 69, doi. 10.1007/s41669-024-00526-2
- By:
- Publication type:
- Article
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Front Cover: Facile Approach to C‐Glucosides by Using a Protecting‐Group‐Free Hiyama Cross‐Coupling Reaction: High‐Yielding Dapagliflozin Synthesis (Chem. Eur. J. 41/2021).
- Published in:
- Chemistry - A European Journal, 2021, v. 27, n. 41, p. 10484, doi. 10.1002/chem.202101994
- By:
- Publication type:
- Article
Facile Approach to C‐Glucosides by Using a Protecting‐Group‐Free Hiyama Cross‐Coupling Reaction: High‐Yielding Dapagliflozin Synthesis.
- Published in:
- Chemistry - A European Journal, 2021, v. 27, n. 41, p. 10488, doi. 10.1002/chem.202101995
- By:
- Publication type:
- Article
Facile Approach to C‐Glucosides by Using a Protecting‐Group‐Free Hiyama Cross‐Coupling Reaction: High‐Yielding Dapagliflozin Synthesis.
- Published in:
- Chemistry - A European Journal, 2021, v. 27, n. 41, p. 10583, doi. 10.1002/chem.202101052
- By:
- Publication type:
- Article
Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.
- Published in:
- Clinical & Experimental Nephrology, 2022, v. 26, n. 12, p. 1242, doi. 10.1007/s10157-022-02260-7
- By:
- Publication type:
- Article
Peritoneal Glucose Uptake Reduction by Sodium-Glucose Co-Transporter 2 Inhibitors in Clinical Peritoneal Dialysis.
- Published in:
- Blood Purification, 2024, v. 53, n. 9, p. 768, doi. 10.1159/000538978
- By:
- Publication type:
- Article
STUDY OF THE IDENTITY OF THE POLYMORPHIC FORM OF API-DAPAGLIFLOSIN DERIVATIVE AND OF ITS PERMANENCY STRUCTURE UNDER THE INFLUENCE OF THE TABLETING PROCESS.
- Published in:
- ScienceRise: Pharmaceutical Science, 2024, v. 49, n. 3, p. 114, doi. 10.15587/2519-4852.2024.289293
- By:
- Publication type:
- Article
STUDY OF THE IDENTITY OF THE POLYMORPHIC FORM OF API-DAPAGLIFLOSIN DERIVATIVE AND OF ITS PERMANENCY STRUCTURE UNDER THE INFLUENCE OF THE TABLETING PROCESS.
- Published in:
- ScienceRise: Pharmaceutical Science, 2024, v. 49, n. 3, p. 86, doi. 10.15587/2519-4852.2024.289293
- By:
- Publication type:
- Article
SGLT-2 INHIBITORS AS POTENTIAL ANTICONVULSANTS: EMPAGLIFLOZIN, BUT NOT DAPAGLIFLOZIN, RENDERS A PRONOUNCED EFFECT AND POTENTIATES THE SODIUM VALPROATE ACTIVITY IN PENTYLENETETRAZOLE-INDUCED SEIZURES.
- Published in:
- ScienceRise: Pharmaceutical Science, 2022, v. 39, n. 5, p. 83, doi. 10.15587/2519-4852.2022.266065
- By:
- Publication type:
- Article
Recurrent Syncope in a Young Man: What Lies Underneath?
- Published in:
- Indian Journal of Clinical Cardiology, 2024, v. 5, n. 3, p. 278, doi. 10.1177/26324636241249530
- By:
- Publication type:
- Article
New Developments in Cardiology with Implications in Clinical Practice.
- Published in:
- Indian Journal of Clinical Cardiology, 2023, v. 4, n. 1, p. 62, doi. 10.1177/26324636221149466
- By:
- Publication type:
- Article
Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
- Published in:
- Cellular Physiology & Biochemistry (Cell Physiol Biochem Press GmbH & Co. KG), 2019, v. 53, n. 5, p. 865, doi. 10.33594/000000178
- By:
- Publication type:
- Article
Journal Scan.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Effect of the use of dapagliflozin in diuresis, natriuriesis, and in ultrafiltration and peritoneal elimination of sodium in patients with refractory heart failure: DAPA-DP study.
- Published in:
- Renal Replacement Therapy, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s41100-024-00594-4
- By:
- Publication type:
- Article
Letter: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2021, v. 30, n. 1, p. 72, doi. 10.7570/jomes20133
- By:
- Publication type:
- Article
Response: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2021, v. 30, n. 1, p. 74, doi. 10.7570/jomes21006
- By:
- Publication type:
- Article
Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2018, v. 27, n. 1, p. 1, doi. 10.7570/jomes.2018.27.1.1
- By:
- Publication type:
- Article
Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2017, v. 26, n. 2, p. 107, doi. 10.7570/jomes.2017.26.2.107
- By:
- Publication type:
- Article
SGLT2 inhibitors.
- Published in:
- SA Pharmaceutical Journal Incorporating Pharmacy Management, 2018, v. 85, n. 1, p. 72
- By:
- Publication type:
- Article
Effect of sodium-glucose transporter 2 inhibitors on bone.
- Published in:
- Journal of Parathyroid Disease, 2023, v. 11, n. 1, p. 1, doi. 10.34172/jpd.2023.11225
- By:
- Publication type:
- Article
三例达榕列净致糖尿病酮症酸中毒的药学监护及文献分析.
- Published in:
- Pharmaceutial Care & Research, 2021, v. 21, n. 2, p. 133, doi. 10.5428/pcar20210211
- By:
- Publication type:
- Article
Triple Fixed-dose combination of Dapagliflozin, Sitagliptin, and Metformin for People with Type 2 Diabetes in Indian Settings.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2024, v. 14, n. 9, p. 66, doi. 10.22270/jddt.v14i9.6692
- By:
- Publication type:
- Article
The MeViDa Study: Bioequivalence Study of FDC of Dapagliflozin, Vildagliptin SR and Metformin SR in Healthy Indian Volunteers: A Randomized, Open-Label, Crossover Study.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2024, v. 14, n. 7, p. 1, doi. 10.22270/jddt.v14i7.6674
- By:
- Publication type:
- Article
The Effectiveness of SGLT2 Inhibitors in CKD Patients.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2023, v. 13, n. 3, p. 141, doi. 10.22270/jddt.v13i3.5750
- By:
- Publication type:
- Article
Dapagliflozin efficacy as an add-on therapy in double and triple-drug regimens: A meta-analysis of randomized control trial.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2023, v. 13, n. 1, p. 76, doi. 10.22270/jddt.v13i1.5863
- By:
- Publication type:
- Article
Bioequivalence study of a fixed-dose combination of Dapagliflozin/ Vildagliptin Sustained Release tablets in healthy adult male subjects: A Randomized, Open-Label, Crossover Study.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2022, v. 12, n. 6, p. 105, doi. 10.22270/jddt.v12i6.5798
- By:
- Publication type:
- Article
Pharmacophore Modeling Study of Sodium Glucose Co-Transporter-2 (Sglt2) Inhibitor for Antidiabetic Activity.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2020, v. 10, n. 1A, p. 78
- By:
- Publication type:
- Article
In-Vitro Antioxidant Activity and Free Radical Scavenging Potential of Phlorizin Derived Sodium Glucose Cotransporter 2 Inhibitor.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2019, v. 9, n. 4, p. 257, doi. 10.22270/jddt.v9i4.3038
- By:
- Publication type:
- Article
Estimation of Metformin Hydrochloride in Bulk and Formulation by UV - Spectroscopic Area Under Curve Method.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2019, v. 9, n. 3, p. 163, doi. 10.22270/jddt.v9i3.2632
- By:
- Publication type:
- Article
Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 753, doi. 10.1007/s40256-024-00669-x
- By:
- Publication type:
- Article
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 3, p. 455, doi. 10.1007/s40256-024-00648-2
- By:
- Publication type:
- Article
Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 2, p. 313, doi. 10.1007/s40256-024-00632-w
- By:
- Publication type:
- Article
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 6, p. 609, doi. 10.1007/s40256-023-00601-9
- By:
- Publication type:
- Article
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 3, p. 323, doi. 10.1007/s40256-023-00578-5
- By:
- Publication type:
- Article
Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 2, p. 127, doi. 10.1007/s40256-022-00564-3
- By:
- Publication type:
- Article
Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 3, p. 325, doi. 10.1007/s40256-021-00506-5
- By:
- Publication type:
- Article
Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 6, p. 701, doi. 10.1007/s40256-021-00503-8
- By:
- Publication type:
- Article
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 3, p. 321, doi. 10.1007/s40256-020-00441-x
- By:
- Publication type:
- Article
The effect of anti-diabetic drugs on the musculoskeletal system in women.
- Published in:
- Romanian Journal of Diabetes Nutrition & Metabolic Diseases, 2021, v. 28, n. 2, p. 223, doi. 10.46389/rjd-2021-1034
- By:
- Publication type:
- Article
The Emerging Role of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes. Focus on Dapagliflozin.
- Published in:
- Romanian Journal of Diabetes Nutrition & Metabolic Diseases, 2016, v. 23, n. 1, p. 113, doi. 10.1515/rjdnmd-2016-0014
- By:
- Publication type:
- Article
DELIVER: Extending the benefits of SGLT-2 inhibitors.
- Published in:
- Global Cardiology Science & Practice, 2023, v. 2023, n. 3, p. 1, doi. 10.21542/gcsp.2023.21
- By:
- Publication type:
- Article
Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07250-z
- By:
- Publication type:
- Article
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-03773-z
- By:
- Publication type:
- Article
Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1205834
- By:
- Publication type:
- Article
VALIDATED RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF CANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN AND METFORMIN.
- Published in:
- International Journal of Pharmaceutical, Chemical & Biological Sciences, 2018, v. 8, n. 1, p. 1
- By:
- Publication type:
- Article
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
- Published in:
- Drugs & Aging, 2016, v. 33, n. 7, p. 511, doi. 10.1007/s40266-016-0382-1
- By:
- Publication type:
- Article
STABILITY-INDICATING RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF ANTIDIABETIC DRUGS, DAPAGLIFLOZIN AND SAXAGLIPTIN.
- Published in:
- Journal of Advanced Scientific Research, 2021, v. 12, p. 67
- By:
- Publication type:
- Article